Spero Therapeutics (SPRO) FCF Margin (QoQ) (2017 - 2026)
Powered by 
Analysis
Spero Therapeutics (SPRO) FCF Margin (QoQ) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.86 Bn | 192.87 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.52 Bn | 176.34 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 131.47 Bn | 123.62 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.16 Bn | 55.98 Bn | 1.37 Bn |
| 6 | Moderna | 53.15 Bn | 48.02 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.20 Bn | 29.89 Bn | 992.69 Mn |
| 8 | Biogen | 31.65 Bn | 30.37 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.30 Bn | 29.30 Bn | 1.16 Mn |
| 10 | Spero Therapeutics | 67.24 Mn | 16.47 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 616,906.00 |
| Dec 31, 2025 | -34,036.00 |
| Sep 30, 2025 | 44,483.00 |
| Jun 30, 2025 | -5,656.00 |
| Mar 31, 2025 | 8,742.00 |
| Dec 31, 2024 | -25,031.00 |
| Sep 30, 2024 | 27,858.00 |
| Jun 30, 2024 | -24,790.00 |
| Mar 31, 2024 | 8,787.00 |
| Dec 31, 2023 | -8,627.00 |
| Sep 30, 2023 | 74,598.00 |
| Jun 30, 2023 | -6,229.00 |
| Mar 31, 2023 | -71,498.00 |
| Dec 31, 2022 | 14,147.00 |
| Sep 30, 2022 | 110,799.00 |
| Jun 30, 2022 | 20,839.00 |
| Mar 31, 2022 | -36,741.00 |
| Dec 31, 2021 | -83,506.00 |
| Sep 30, 2021 | 16,020.00 |
| Jun 30, 2021 | -10,977.00 |